IRIS
ATZENI, Fabiola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.403
EU - Europa 8.298
AS - Asia 5.953
SA - Sud America 2.383
AF - Africa 220
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 8
Totale 25.276
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.196
RU - Federazione Russa 5.016
SG - Singapore 2.674
BR - Brasile 2.041
CN - Cina 1.404
IE - Irlanda 1.242
HK - Hong Kong 717
SE - Svezia 638
IT - Italia 434
VN - Vietnam 308
FR - Francia 282
DE - Germania 197
IN - India 142
AR - Argentina 124
PL - Polonia 108
GB - Regno Unito 106
BD - Bangladesh 104
IQ - Iraq 80
MX - Messico 72
CA - Canada 68
ZA - Sudafrica 68
TR - Turchia 64
NL - Olanda 55
FI - Finlandia 46
UZ - Uzbekistan 46
EC - Ecuador 45
PK - Pakistan 44
JP - Giappone 41
VE - Venezuela 41
ID - Indonesia 39
CO - Colombia 32
AT - Austria 31
MA - Marocco 28
EG - Egitto 27
UA - Ucraina 27
PY - Paraguay 26
SA - Arabia Saudita 25
BE - Belgio 23
CL - Cile 23
AE - Emirati Arabi Uniti 22
JO - Giordania 22
KE - Kenya 22
BO - Bolivia 21
ES - Italia 21
NP - Nepal 19
KZ - Kazakistan 18
PE - Perù 18
IL - Israele 17
AZ - Azerbaigian 16
DZ - Algeria 16
TN - Tunisia 16
PH - Filippine 15
IR - Iran 14
JM - Giamaica 13
KG - Kirghizistan 12
PA - Panama 12
LB - Libano 11
OM - Oman 11
MY - Malesia 10
PS - Palestinian Territory 10
UY - Uruguay 10
DO - Repubblica Dominicana 9
QA - Qatar 9
SN - Senegal 9
CR - Costa Rica 8
SY - Repubblica araba siriana 8
TH - Thailandia 8
AL - Albania 7
BY - Bielorussia 7
CI - Costa d'Avorio 7
ET - Etiopia 7
PT - Portogallo 7
AM - Armenia 6
CZ - Repubblica Ceca 6
EU - Europa 6
RO - Romania 6
TT - Trinidad e Tobago 6
AO - Angola 5
AU - Australia 5
BH - Bahrain 5
CH - Svizzera 5
DK - Danimarca 5
GE - Georgia 5
KR - Corea 5
NI - Nicaragua 5
RS - Serbia 5
GT - Guatemala 4
HN - Honduras 4
TW - Taiwan 4
BG - Bulgaria 3
CY - Cipro 3
GA - Gabon 3
GR - Grecia 3
LT - Lituania 3
MN - Mongolia 3
NG - Nigeria 3
SV - El Salvador 3
BN - Brunei Darussalam 2
CG - Congo 2
EE - Estonia 2
Totale 25.233
Salva come PNG Salva come JPEG
Città #
Moscow 1.751
Singapore 1.526
Ashburn 1.290
Dublin 1.240
Chandler 1.009
Dallas 916
Hong Kong 708
Beijing 577
Nyköping 456
New York 342
San Jose 298
Princeton 271
Jacksonville 250
Dearborn 245
The Dalles 230
Medford 229
Lauterbourg 214
Des Moines 204
São Paulo 172
Cambridge 166
Los Angeles 161
Redondo Beach 116
Buffalo 101
Ho Chi Minh City 101
Warsaw 100
Messina 96
Rio de Janeiro 85
Santa Clara 76
Ann Arbor 74
Munich 70
Hanoi 67
Tianjin 60
Belo Horizonte 59
Frankfurt am Main 59
Pune 59
Wilmington 59
Orem 58
Guangzhou 51
Council Bluffs 50
Nanjing 43
Tashkent 42
Shenyang 40
Tokyo 39
Jinan 33
Baghdad 30
Nuremberg 30
Brasília 28
Brooklyn 28
Johannesburg 28
Milan 28
Porto Alegre 28
Rome 27
Seattle 27
Buenos Aires 25
London 25
Amsterdam 24
Campinas 24
San Francisco 24
Boardman 23
Montreal 23
Shanghai 23
Chennai 22
Falls Church 21
Mexico City 21
Turku 21
Brussels 20
Phoenix 20
Salvador 20
Curitiba 19
Ningbo 19
San Mateo 19
Amman 18
Atlanta 18
Catania 18
Haikou 18
Hebei 18
Nairobi 18
Cape Town 17
Dhaka 17
Fortaleza 17
Vienna 17
Zhengzhou 17
Caxias do Sul 16
Guarulhos 16
Changsha 15
Guayaquil 15
Hangzhou 15
Norwalk 15
Quito 15
Aracaju 14
Baku 14
Caracas 14
Chicago 14
Dong Ket 14
Haiphong 14
Istanbul 14
Nanchang 14
Santo André 14
Asunción 13
Belém 13
Totale 14.892
Salva come PNG Salva come JPEG
Nome #
CORRELATION BETWEEN DISEASE ACTIVITY AND CARDIOVASCULAR PARAMETERS IN PATIENTS WITH ANKYLOSING SPONDYLITIS 196
Adverse events, clinical considerations and management recommendations in rheumatoid arthritis patients treated with JAK inhibitors 192
CARDIOVASCULAR EVALUATION USING NON-INVASIVE IMAGING METHODS IN PATIENTS WITH ANKYLOSING SPONDYLITIS BEFORE AND AFTER 12 MONTHS OF TREATMENT WITH ANTI-TNF DRUGS 187
Algo-dysfunctional syndromes: a critical digest of the recent literature 184
A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis 176
Certainties and uncertainties concerning the contribution of pericytes to the pathogenesis of systemic sclerosis 174
Anti-tumour necrosis factor-α antibodies and B cell homeostasis in human inflammatory bowel diseases 172
Central nervous system involvement in rheumatoid arthritis patients and the potential implications of using biological agents 166
Biomarkers in Rheumatoid Arthritis 160
BODY MASS INDEX, SMOKING STATUS AND RESPONSE TO RITUXIMAB IN RHEUMATOID ARTHRITIS: A REAL-LIFE STUDY. 157
Cancer risk and tumour necrosis factor inhibitors in patients with inflammatory arthritis 155
A Review of Chronic Musculoskeletal Pain: Central and Peripheral Effects of Diclofenac 154
Accelerated subcutaneous nodulosis in patients with rheumatoid arthritis treated with tocilizumab: A case series 149
A randomised controlled trial comparing duloxetine and acetyl L-carnitine in fibromyalgic patients: preliminary data 148
CLINICAL AND ULTRASONOGRAPHIC EVALUATION IN A COHORT OF SUSTAINED REMISSION RHEUMATOID ARTHRITIS PATIENTS AFTER STOPPING BIOLOGIC THERAPY: A SINGLE CENTER EXPERIENCE , 147
Assessment of enthesis in patients with psoriatic arthritis and fibromyalgia using clinical examination and ultrasound 147
Safety Profile of Biologics Used in Rheumatology: An Italian Prospective Pharmacovigilance Study 146
Recurrent intracranial hemorrhage and cerebral venous sinus thrombosis: an atypical case of Neuro-Behçet’s Syndrome 146
Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: A one-year prospective study 138
A proteinuria cut-off level of 0.7 g /day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: Data from the MAINTAIN Nephritis Trial 136
Anti-adalimumab and anti-certolizumab antibodies titers after discontinuation of adalimumab: Two case reports 134
An update on emerging drugs for fibromyalgia treatment 134
B Lymphocyte intestinal homing in inflammatory bowel disease 133
A possible link between ankylosing spondylitis and periodontitis: A systematic review and meta-analysis 132
RELATIONSHIP BETWEEN ULTRASONOGRAPHIC SALIVARY GLANDS ABNORMALITIES AND SUBCLINICAL CARDIOVASCULAR INVOLVEMENT IN PATIENTS WITH PRIMARY SJÖGREN SYNDROME 132
The microbiome in connective tissue diseases and vasculitides: An updated narrative review 129
The neuropathic pain features in Psoriatic Arthritis: a cross-sectional evaluation of prevalence and associated factors 127
Biological agents in rheumatoid arthritis: A cross-link between immune tolerance and immune surveillance 126
Correlations between immunogenicity, drug levels, and disease activity in an Italian cohort of rheumatoid arthritis patients treated with tocilizumab 125
Are the ACR 2010 diagnostic criteria for fibromyalgia better than the 1990 criteria? 124
A Proposed Serum Calprotectin IgG Cut-Off Level for Diagnosing Inflammatory Arthritis 124
Cross Cultural Adaptation and Validation of Italian Version of the Leeds Assessment of Neuropathic Symptoms and Signs Scale and Pain DETECT Questionnaire for the Distinction between Nociceptive and Neuropathic Pain 122
Retrospective evaluation of patient profiling and effectiveness of apremilast in an Italian multicentric cohort of psoriatic arthritis patients 120
MEASUREMENT OF SERUM ALPHA-KLOTHO IN SYSTEMIC SCLEROSIS PATIENTS: RESULTS FROM A PIVOTAL STUDY. 120
An open, randomized comparison study of cyclosporine A, cyclosporine A + methotrexate and cyclosporine A + hydroxychloroquine in the treatment of early severe rheumatoid arthritis 119
From autoinflammation to autoimmunity: old and recent findings 119
Subclinical atherosclerosis and history of cardiovascular events in Italian patients with rheumatoid arthritis 117
One year in review 2019: fibromyalgia 117
Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry 115
Systemic rheumatic diseases: from biological agents to small molecules 114
Failure of anti-TNF treatment in patients with rheumatoid arthritis: The pros and cons of the early use of alternative biological agents 113
Safety of Abatacept in Rheumatoid Arthritis with Serologic Evidence of Past or Present Hepatitis B Virus Infection 111
Measuring psoriatic disease in clinical practice. An expert opinion position paper 111
PLA1/A2 polymorphism of the platelet glycoprotein receptors IIIA in Behçet's disease 109
Cardiovascular risk in ankylosing spondylitis and the effect of anti-TNF drugs: a narrative review 109
Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction. 109
Longterm retention of tumor necrosis factor-α inhibitor therapy in a large Italian cohort of patients with rheumatoid arthritis from the GISEA Registry: An appraisal of predictors 108
Paradoxical Expansion of Th1 and Th17 Lymphocytes in Rheumatoid Arthritis Following Infliximab Treatment: a Possible Explanation for a Lack of Clinical Response 108
Immunogenicity and autoimmunity during anti-TNF therapy 107
Safety of Abatacept in Italian Patients with Rheumatoid Arthritis and Interstitial Lung Disease: A Multicenter Retrospective Study 107
Noninvasive imaging methods for evaluating cardiovascular involvement in patients with rheumatoid arthritis before and after anti-TNF drug treatment 107
Hyperbaric oxygen treatment of fibromyalgia: a prospective observational clinical trial 107
Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: Results from the GISEA register 107
Ultrasonographyc Evaluation of Metacarpophalangeal Joints Can be Useful in the Differential Diagnosis of Early Rheumatoid Arthritis and Early Spondyloarthritis. A Monocentric Preliminary Study 105
TNF inhibitors in rheumatoid arthritis and spondyloarthritis: Are they the same? 105
Anti-citrullinated peptide antibodies and rheumatoid factor isotypes in the diagnosis of rheumatoid arthritis: An assessment of combined tests 104
CC chemokine receptor 5 polymorphism in Italian patients with Beḩet's disease 103
Retrotransposons shuttling genetic and epigenetic information from the nuclear to the mitochondrial compartment: Do they play a pathogenetic role in scleroderma? 103
Impaired lung transfer factor in fibromyalgia syndrome 103
What are the dangers of biological therapy discontinuation or dose reduction strategies when treating rheumatoid arthritis? 102
Chronic widespread pain in the spectrum of rheumatological diseases 102
Co-Occurrence and Characteristics of Patients With Axial Spondyloarthritis Who Meet Criteria for Fibromyalgia: Results From a UK National Register 102
Psoriatic arthritis: From pathogenesis to pharmacologic management 102
EULAR recommendations for management of fibromyalgia 102
EULAR revised recommendations for the management of fibromyalgia 101
Pain in systemic sclerosis 100
How immunological profile drives clinical phenotype of primary Sjögren's syndrome at diagnosis: analysis of 10,500 patients (Sjögren Big Data Project) 100
Fibromyalgia: an update on clinical characteristics, aetiopathogenesis and treatment 100
Efficacy and Safety of Biosimilar and Originator Etanercept in Rheumatoid Arthritis Patients: Real-Life Data 100
Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: Real-life data from the LORHEN registry 99
Malar rash is a predictor of subclinical airway inflammation in patients with systemic lupus erythematosus: a pilot study 99
Differential Diagnosis of Vasovagal Syncope: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. 99
Efficacy of Cannabis Flos in Patients with Fibromyalgia: A Monocentric 99
EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update 97
Measurement of Serum Klotho in Systemic Sclerosis 97
Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry 97
Repeat kidney biopsies fail to detect differences between azathioprine and mycophenolate mofetil maintenance therapy for lupus nephritis: data from the MAINTAIN Nephritis Trial 96
AxSpA patients who also meet criteria for fibromyalgia: identifying distinct patient clusters using data from a UK national register (BSRBR-AS) 96
Prescribing motivations and patients’ characteristics related to the use of biologic drugs in adult-onset Still’s disease: analysis of a multicentre “real-life” cohort 96
DOSE REDUCTION IN PATIENTS WITH RHEUMATOID ARTHRITIS RESPONDING TO THE STANDARD RITUXIMAB REGIMEN. 96
Cardiovascular Imaging Techniques in Systemic Rheumatic Diseases 95
PREVALENCE OF CHRONIC WIDESPREAD PAIN IN SSC PATIENTS: PRELIMINARY DATA 95
Patients Failing to Fulfill 2016 Criteria for Fibromyalgia Represent a Truly Different Population Subset 95
Study of entheses in patients with spondyloarthritis and inflammatory bowel disease with and without fibromyalgia: The importance of ultrasonography 95
Adding medical cannabis to standard analgesic treatment for fibromyalgia: a prospective observational study 95
Infections and Biological Therapy in Patients with Rheumatic Diseases 94
SDAI AS PREDICTOR OF 1-YEAR EFFICACY OF THE FIRST TNF BLOCKER IN CLINICAL PRACTICE. 94
Abnormalities of cardiovascular neural control and reduced orthostatic tolerance in patients with primary fibromyalgia 93
The effect of drugs used in rheumatology for treating SARS-CoV2 infection 93
The profiling of axial spondyloarthritis patient candidate to a biologic therapy: Consensus from a Delphi-panel of Italian experts 92
Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks 91
Identification of the clinical features distinguishing psoriatic arthritis and fibromyalgia 91
Laboratory monitoring of biological therapies in rheumatology: The role of immunogenicity 91
Efficacy of cyclophosphamide in treating connective tissue disease-related interstitial lung diseases 90
Web/Internet-based telemonitoring of a randomized controlled trial evaluating the time-integrated effects of a 24-week multicomponent intervention on key health outcomes in patients with fibromyalgia 90
Controlled-release pregabalin in the treatment of fibromyalgia 89
Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren’s syndrome at diagnosis in 8310 patients: A cross-sectional study from the Big Data Sjögren’s Project Consortium 89
Concerns about the safety of anti-TNF agents when treating rheumatic diseases 89
The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: Results of an italian multicentre study 88
Serum klotho concentrations inversely correlate with the severity of nailfold capillaroscopic patterns in patients with systemic sclerosis 88
Totale 11.668
Salva come PNG Salva come JPEG
Categoria #
all - tutte 104.925
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 104.925
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202117 0 0 0 0 0 0 0 0 0 0 0 17
2021/20221.179 9 60 3 30 96 21 27 51 36 55 169 622
2022/20233.443 311 221 155 315 169 347 19 199 1.556 14 110 27
2023/20241.113 94 133 188 83 69 383 7 33 4 32 7 80
2024/20254.812 74 44 93 294 148 152 146 1.060 1.340 335 395 731
2025/202613.163 484 947 1.149 759 1.131 3.036 1.653 1.444 1.375 634 258 293
Totale 25.915